Effect of Hypercapnia Treatment on Respiratory Recovery After Spinal Cord Injury
Launched by VA OFFICE OF RESEARCH AND DEVELOPMENT · Sep 9, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment for sleep apnea in veterans who have a spinal cord injury (SCI). Researchers want to find out if daily hypercapnia treatments—essentially, breathing in air with higher levels of carbon dioxide—can help improve breathing problems and reduce sleep apnea in these patients. The study will last for two weeks, and it aims to gather important information that could lead to better therapies for respiratory issues in people with spinal cord injuries.
To participate in this trial, potential volunteers need to be adults who have had a spinal cord injury for more than six months and have signs of sleep-disordered breathing. This includes veterans with varying levels of injury severity, as long as they can still breathe on their own. Some individuals, like those who have had recent serious health problems or are unable to consent for themselves, won’t be eligible. Participants can expect to receive daily treatments and will be monitored closely during the study. This is an exciting opportunity that could help improve the health and quality of life for those affected by spinal cord injuries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients with chronic SCI/D (\>6 months post-injury)
- • American Spinal Injury Association (ASIA) classification A-D who have evidence of SDB (excluding those with no evidence of a neurologic deficit based on ASIA classification)
- • Able-bodied patients (without SCI/D0 who have OSA.
- Exclusion Criteria:
- • Receiving continuous mechanical ventilation (except PAP therapy which is considered usual treatment for SDB
- • Severe congestive heart failure with ejection fraction \<35%
- • Recent health event that may affect sleep
- • stroke
- • acute myocardial infarction
- • recent surgery
- • hospitalization
- • Alcohol or substance abuse (\<90 days sobriety)
- • Self-described as too ill to engage in study procedures
- • Evidence of hypercapnia on spontaneous breathing (end-tidal CO2 \>50 mmHg)
- • Unable to provide self-consent for participation
About Va Office Of Research And Development
The VA Office of Research and Development (ORD) is dedicated to advancing the health and well-being of veterans through innovative research initiatives. As a pivotal sponsor of clinical trials, ORD focuses on a broad spectrum of health-related topics, including mental health, rehabilitation, and chronic disease management, ensuring that findings are directly applicable to the unique needs of the veteran population. With a commitment to scientific excellence and collaboration, ORD promotes rigorous study designs and ethical standards, facilitating the translation of research discoveries into improved clinical practices and policies that enhance veteran care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Detroit, Michigan, United States
Detroit, Michigan, United States
Patients applied
Trial Officials
Abdulghani Sankari, MD PhD
Principal Investigator
John D. Dingell VA Medical Center, Detroit, MI
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials